Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/25/2019 |
| Start Date: | February 2011 |
| End Date: | February 2020 |
The purpose of this study is to try to learn more about how small molecule kinase inhibitor
medications work in treating lung cancer. Crizotinib (PF-02341066) is a drug that has been
shown to shrink tumors in some patients with lung cancer. While the investigators know how
this drug works to stop the growth of tumors that depend on change in the gene named ALK
(also called EML4-ALK), the investigators do not know why the drug stops working. The
investigators would like to examine the tumor to help us better understand why crizotinib has
stopped working as well as it once did. The tumor will be examined with multiple tests to
look for the reason that crizotinib stopped working.
medications work in treating lung cancer. Crizotinib (PF-02341066) is a drug that has been
shown to shrink tumors in some patients with lung cancer. While the investigators know how
this drug works to stop the growth of tumors that depend on change in the gene named ALK
(also called EML4-ALK), the investigators do not know why the drug stops working. The
investigators would like to examine the tumor to help us better understand why crizotinib has
stopped working as well as it once did. The tumor will be examined with multiple tests to
look for the reason that crizotinib stopped working.
Inclusion Criteria:
- ≥18 years of age
- Histologically proven diagnosis of NSCLC at MSKCC Tumor positive for a translocation
or inversion event involving the ALK gene locus
- Clinical response to treatment with crizotinib as defined by either:
Radiographic partial or complete response defined by RECIST or WHO
OR:
Radiographic stable disease for at least 8 weeks
- Radiographic progression of disease amenable to biopsy while on treatment with
crizotinib as defined by RECIST or WHO
- Signed informed consent
Exclusion Criteria:
- Deemed by their treating physician to be medically unfit for biopsy
- Women who are pregnant or breast-feeding
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
